Identification of glucose-dependant insulin secretion targets in pancreatic β cells by combining defined-mechanism compound library screening and siRNA gene silencing

Journal of Biomolecular Screening

Volumn 13, Issue 2, 2008, Pages 128-134

  Weizhen Wu, ^a   Jin Shang, ^a   Yue Feng, ^a   Thompson, Chris M ^a   Horwitz, Sarah ^a   Thompson, John R ^a   MacIntyre, Euan D ^a   Thornberry, Nancy A ^a   Chapman, Kevin ^a   Zhou, Yun Ping ^a   Howard, Andrew D ^a   Jing Li, ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Compound library screen; Insulin secretion; siRNA; Type 2 diabetes

Indexed keywords

ADRENERGIC RECEPTOR; CALCIUM CHANNEL; CYCLIC AMP; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLUCOSE; INSULIN; PHOSPHODIESTERASE; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRD2 GENE; GENE; GENE LIBRARY; GENE SILENCING; HORMONAL REGULATION; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; RNA INTERFERENCE; VALIDATION PROCESS;

ANIMALS; CELLS, CULTURED; DOPAMINE ANTAGONISTS; GENE LIBRARY; GENE SILENCING; GLUCOSE; INSULIN; INSULIN-SECRETING CELLS; METABOLIC NETWORKS AND PATHWAYS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; RNA, MESSENGER; RNA, SMALL INTERFERING;

RATTUS;

EID: 39149114759     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057107313763     Document Type: Article

References (40)

1. Kola I., Landis J: Can the pharmaceutical industry reduce attrition rates ? Nat Rev Drug Discov 2004 ; 3: 711-715.
2. Schadt EE, Monks SA, Friend SH: A new paradigm for drug discovery: integrating clinical, genetic, genomic and molecular phenotype data to identify drug targets. Biochem Soc Trans 2003 ; 31: 437-443.
3. Schadt EE, Monks SA, Drake TA, Lusis AJ, Che N., Colinayo V.,, et al. Genetics of gene expression surveyed in maize, mouse and man. Nature 2003 ; 422: 297-302.
4. Schadt EE, Sachs A., Friend S.: Embracing complexity, inching closer to reality. Sci STKE 2005 ; 295: pe40.
5. Mehrabian M., Allayee H., Stockton J., Lum PY, Drake TA, Castellani LW,, et al. Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nat Genet 2005 ; 37: 1224-1233.
6. Cervino AC, Li G., Edwards S., Zhu J., Laurie C., Tokiwa G.,, et al. Integrating QTL and high-density SNP analyses in mice to identify Insig2 as a susceptibility gene for plasma cholesterol levels. Genomics 2005 ; 86: 505-517.
7. Stockwell BR: Chemical genetics: ligand-based discovery of gene function. Nat Rev Genet 2000 ; 1: 116-125.
8. Lokey RS: Forward chemical genetics: progress and obstacles on the path to a new pharmacopoeia. Curr Opin Chem Biol 2003 ; 7: 91-96.
9. Liu J., Farmer JD, Lane WS, Friedman J., Weissman I., Schreiber SL: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991 ; 66: 807-815.
10. Brown EJ, Albers MW, Shin TB, Ichikawa K., Keith CT, Lane WS,, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994 ; 369: 756-758.
11. Sin N., Meng L., Wang MQ, Wen JJ, Bornmann WG, Crews CM: The antiangiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A 1997 ; 94: 6099-6103.
12. Newgard CB, Lu D., Jensen MV, Schissler J., Boucher A., Burgess S.,, et al. Stimulus/secretion coupling factors in glucose-stimulated insulin secretion: insights gained from a multidisciplinary approach. Diabetes 2002 ;Suppl 3: S389-S393.
13. Malo N., Hanley JA, Cerquozzi S., Pelletier J., Nadon R.: Statistical practice in high-throughput screening data analysis. Nat Biotechnol 2006 ; 24: 167-175.
14. Lacy PE, Kostianovsky M.: Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967 ; 16: 35-39.
15. Herrington J., Zhou YP, Bugianesi RM, Dulski PM, Feng Y., Warren VA,, et al. Blockers of the delayed-rectifier potassium current in pancreatic beta-cells enhance glucose-dependent insulin secretion. Diabetes 2006 ; 55: 1034-1042.
16. Zhou YP, Berggren PO, Grill V.: A fatty acid-induced decrease in pyruvate dehydrogenase activity is an important determinant of beta-cell dysfunction in the obese diabetic db/db mouse. Diabetes 1996 ; 45: 580-586.
17. Hohmeier HE, Mulder H., Chen G., Henkel-Rieger R., Prentki M., Newgard CB: Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 2000 ; 49: 424-430.
18. Boucher A., Lu D., Burgess SC, Telemaque-Potts S., Jensen MV, Mulder H.,, et al. Biochemical mechanism of lipid-induced impairment of glucose-stimulated insulin secretion and reversal with a malate analogue. J Biol Chem 2004 ; 279: 27263-27271.
19. Schisler JC, Jensen PB, Taylor DG, Becker TC, Knop FK, Takekawa S.,, et al. The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells. Proc Natl Acad Sci U S A 2005 ; 102: 7297-7302.
20. Jensen MV, Joseph JW, Ilkayeva O., Burgess S., Lu D., Ronnebaum SM,, et al. Compensatory responses to pyruvate carboxylase suppression in islet beta-cells: preservation of glucose-stimulated insulin secretion. J Biol Chem 2006 ; 281: 22342-22351.
21. Smith PA, Rorsmann P., Ashcroft FM: Modulation of dihydropyridine- sensitive Ca2+ channels by glucose metabolism in mouse pancreatic beta-cells. Nature 1989 ; 342: 550-553.
22. Ashcroft FM: Ca2+ channels and excitation-contraction coupling. Curr Opin Cell Biol 1991 ; 3: 671-675.
23. Ashcroft FM, Proks P., Smith PA, Ammala C., Bokvist K., Rorsman P.: Stimulus-secretion coupling in pancreatic beta cells. J Cell Biochem 1994 ; 55 (Suppl): 54-65.
24. Sharp GW: The adenylate cyclase-cyclic AMP system in islets of Langerhans and its role in the control of insulin release. Diabetologia 1979 ; 16: 287-296.
25. Drucker DJ, Philippe J., Mojsov S., Chick WL, Habener JF: Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987 ; 84: 3434-3438.
26. Leibowitz MD, Biswas C., Brady EJ, Conti M., Cullinan CA, Hayes NS,, et al. A novel glucose-dependent insulin secretagogue is a phophodiesterase inhibitor. Diabetes 1995 ; 44: 67-74.
27. Pyne NJ, Furman BL: Cyclic nucleotide phosphodiesterases in pancreatic islets. Diabetologia 2003 ; 46: 1179-1189.
28. Johansson SM, Salehi A., Sandstrom ME, Westerblad H., Lundquist I., Carlsson PO,, et al. A(1) receptor deficiency causes increased insulin and glucagon secretion in mice. Biochem Pharmacol 2007 ; 74: 1628-1635.
29. Hillaire-Buys D., Bertrand G., Gross R., Loubatieres-Mariani MM: Evidence for an inhibitory A1 subtype adenosine receptor on pancreatic insulin-secreting cells. Eur J Pharmacol 1987 ; 136: 109-112.
30. Peterhoff M., Sieg A., Brede M., Chao CM, Hein L., Ullrich S.: Inhibition of insulin secretion via distinct signaling pathways in alpha2-adrenoceptor knockout mice. Eur J Endocrinol 2003 ; 149: 343-350.
31. Devedjian JC, Pujol A., Cayla C., George M., Casellas A., Paris H.,, et al. Transgenic mice overexpressing alpha2A-adrenoceptors in pancreatic beta-cells show altered regulation of glucose homeostasis. Diabetologia 2000 ; 43: 899-906.
32. Mojsov S., Weir GC, Habener JF: Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987 ; 79: 616-619.
33. Fehmann HC, Goke B., Goke R., Trautmann ME, Arnold R.: Synergistic stimulatory effect of glucagon-like peptide-1 (7-36) amide and glucose-dependent insulin-releasing polypeptide on the endocrine rat pancreas. FEBS Lett 1989 ; 252: 109-112.
34. Alberti KG, Christensen NJ, Christensen SE, Hansen AP, Iversen J., Lundbaek K.,, et al. Inhibition of insulin secretion by somatostatin. Lancet 1973 ; 2: 1299-1301.
35. Johnson DG, Ensinck JW, Koerker D., Palmer J., Goodner CJ: Inhibition of glucagon and insulin secretion by somatostatin in the rat pancreas perfused in situ. Endocrinology 1975 ; 96: 370-374.
36. Ericson LE, Hakanson R., Lundquist, I.: Accumulation of dopamine in mouse pancreatic B-cells following injection of L-DOPA Localization to secretory granules and inhibition of insulin secretion. Diabetologia 1977 ; 13: 117-124.
37. Arneric SP, Chow SA, Long JP, Fischer LJ: Inhibition of insulin release from rat pancreatic islets by drugs that are analogues of dopamine. Diabetes 1984 ; 33: 888-893.
38. Rubi B., Ljubicic S., Pournourmohammadi S., Carobbio S., Armanet M., Bartley C.,, et al. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem 2005 ; 280: 36824-36832.
39. Wishart DS, Knox C., Guo AC, Shrivastava S., Hassanali M., Stothard P.,, et al. Drug Bank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006 ; 34: D668 - D672.
40. Overington JP, Al-Lazikani B., Hopkins AL: How many drug targets are there ? Nat Rev Drug Discov 2006 ; 5: 993-996.